Search results
Results from the WOW.Com Content Network
Endo Pharmaceuticals Holdings was created as a result of a $277 million management buyout of the division from DuPont Merck in 1997, led by Carol Ammon. [6] Through the merger with Algos, it changed name again to Endo Pharmaceuticals Holdings Inc. and began trading as a public company. [9]
In 2014, Endo Pharmaceuticals, an American pharmaceutical company, acquired most of the assets of Paladin Labs for $3 billion, or $151 a share, a 100 times increase from its IPO price. [5] As part of the transaction, Knight Therapeutics was spun-off to the shareholders of Paladin, with the rights to Impavido, a leishmaniasis drug. [6]
Mallinckrodt Pharmaceuticals plc is an American-Irish domiciled manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it generated 90% of its sales from the U.S. healthcare system.
The more Endo Pharmaceuticals (NAS: ENDP) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders ...
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug company Endo Pharmaceuticals Holdings (NAS: ENDP) has ...
Endo Pharmaceuticals Holdings (NAS: ENDP) reported earnings on May 1. Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q1), Endo Pharmaceuticals ...
Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis (now Allergan).
India-headquartered contract research organization GVK Biosciences announced in a press release Monday that it has entered into an agreement with Endo Pharmaceuticals, part of Endo Health Solutions .